5 results match your criteria: "The Hebrew University of Jerusalem- Hadassah Medical Center[Affiliation]"
Isr J Health Policy Res
August 2024
Braun School of Public Health and Community Medicine, Faculty of Medicine, The Hebrew University of Jerusalem - Hadassah Medical Center, Ein Kerem, PO Box 12272, 911200, Jerusalem, Israel.
Glob Public Health
January 2023
Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
Int J Environ Res Public Health
January 2021
Department of Medicine, The Hebrew University of Jerusalem-Hadassah Medical Center, Jerusalem 12000, Israel.
Improving global health requires making current and future drugs more effective and affordable. While healthcare systems around the world are faced with increasing costs, branded and generic drug companies are facing the challenge of creating market differentiators. Two of the problems associated with the partial or complete loss of response to chronic medications are a lack of adherence and compensatory responses to chronic drug administration, which leads to tolerance and loss of effectiveness.
View Article and Find Full Text PDFBiomacromolecules
August 2010
Institute for Drug Research, School of Pharmacy, and Department of Clinical Microbiology and Infectious Diseases, The Hebrew University of Jerusalem-Hadassah Medical Center, P.O. Box 12065, Jerusalem 91120, Israel.
Conjugation of poorly soluble drugs to polysaccharides affects their solubility, pharmacokinetics (PK), and pharmacodynamics. The need for amphotericin B (AmB) analog with improved solubility and reduced toxicity is immense. Conjugation of AmB to arabinogalactan (AG) produced a highly soluble AmB-AG conjugate, with high and low molecular weight (H-M(w) and L-M(w)) fractions.
View Article and Find Full Text PDFRegen Med
January 2009
Skeletal Biotech Lab, Hebrew University, The Hebrew University of Jerusalem- Hadassah Medical Center, Jerusalem, Israel.
Spine disorders and intervertebral disc degeneration are considered the main causes for the clinical condition commonly known as back pain. Spinal fusion by implanting autologous bone to produce bony bridging between the two vertebrae flanking the degenerated-intervertebral disc is currently the most efficient treatment for relieving the symptoms of back pain. However, donor-site morbidity, complications and the long healing time limit the success of this approach.
View Article and Find Full Text PDF